US-based biotechnology company Exelixis has signed a clinical trial collaboration agreement with Arcus Biosciences to analyse zanzalintinib along with AB521 in a Phase Ib/II clinical trial.

The combination therapy will be assessed for advanced solid tumours, including clear cell renal cell carcinoma.

The open-label STELLAR-009 trial will determine the recommended dose of zanzalintinib with AB521 in its dose-finding stage.

Sponsored by Exelixis and jointly funded by Arcus, the trial is due to begin enrolling subjects before the end of this year.

Exelixis product development AND medical affairs executive vice-president and chief medical officer Amy Peterson said: “We are excited to learn more about the potential effects of zanzalintinib plus Arcus’ HIF-2⍺ inhibitor, as these two molecules approach the inhibition of cancer cell proliferation and tumour angiogenesis from differing angles, and combination therapy may provide better outcomes than either therapy alone. 

“We have a long-established commitment to advancing treatment options in kidney cancer, and we are eager to maximise the potential of zanzalintinib through this collaboration with Arcus and look forward to advancing the combination in the clinic.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Zanzalintinib is a tyrosine kinase inhibitor (TKI) that hinders the functioning of receptor tyrosine kinases associated with the growth and spread of cancer.

It is in development to potentially treat various advanced solid tumours such as colorectal, genitourinary and head and neck cancers.

Arcus Biosciences chief medical officer Dimitry Nuyten said: “We are excited to partner with Exelixis on the STELLAR-009 study to determine the best-in-class potential of AB521 in combination with zanzalintinib and look forward to generating a robust set of data to move this combination into full development.

“The STELLAR-009 study is an important step in the development of AB521 and enables a cost-effective path to evaluating our HIF-2⍺ inhibitor with a next-generation TKI.”